IND approval for the TORCH trial with respect to ATG-008 (onatasertib) was received in Taiwan

We and Karyopharm established cooperation to develop and commercialize four clinical-stage drug candidates, including ATG-010 (selinexor), in mainland China and certain other Asian countries and regions

IND approvals for the TORCH trial with respect to ATG-008 (onatasertib) were received in mainland China and South Korea

ATG-008 was selected into National Science and Technology Major Project